Genincode (GENI.L) Stock Price

Genincode Price

LSE·CLOSED
0.01
​
Market closed

Revenue has compounded at 8.2% per year over the past 6 years to 3.08 M GBP. Genincode's net margin stands at -185.5%, up from -358.9% several years earlier.

Genincode stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genincode business model & stock analysis

GENinCode Plc generates revenue through its genetic risk assessment products for cardiovascular disease, including Cardio Incode, Lipid Incode, Sudd Incode, Roca Test, Thrombo, and Thrombo Incode Reproductive Health. The company targets healthcare practitioners who use its genomic precision testing, combining polygenic technology, molecular testing, genotyping, sequencing, and AI bioinformatics to assess patient DNA risk. Its products integrate genetic and clinical data to provide predictive care strategies for cardiovascular disease prevention. The firm serves medical professionals seeking advanced tools for patient risk evaluation and treatment planning. The company's wholly owned subsidiaries, GENinCode S.L.U. and GENinCode U.S. INC., support its global operations in risk assessment and prevention services. GENinCode Plc's focus on cardiovascular disease risk assessment leverages AI-driven bioinformatics to deliver tailored preventative care solutions. Healthcare providers utilize its comprehensive testing suite to enhance clinical decision-making and patient outcomes in cardiovascular health management.

Frequently asked questions about Genincode

5 analysts currently rate the Genincode stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Genincode to generate revenue of 3.20 M GBP and earnings per share of -0.00 GBP.

Converted at the current exchange rate, the Genincode share trades at 0.01 EUR (0.01 GBP).

The Genincode share (GENI.L) is listed on 3 stock exchanges, including: London (GENI.L), Frankfurt (9PL.F).

The expected revenue of Genincode is 3.20 M GBP. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Genincode is -20,368.48 GBP. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Genincode is currently -84.14. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Genincode stock.

The price-to-sales ratio (P/S) of Genincode is currently 0.54. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Genincode stock.

The Eulerpool Quality Score for Genincode is 3/10.

The ISIN of Genincode is GB00BL97B504. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Genincode is A3C31Y. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Genincode is GENI.L. The ticker symbol is used to trade Genincode shares on the stock exchange.

Fair ValueTerminal
0.00 GBP
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Providers & Services
Number of shares
Employees
Revenue per Employee
109,857.14 GBP
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
GBP
Initial public offering
Jul 22, 2021
ISIN
GB00BL97B504
Cusip
G392AC106
Market capitalization
1.72 M GBPMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-84.14
P/Ee 2027
-85.34
P/Ee 2028
—
P/Ee 2029
—
P/S
P/Se
0.54
EV/EBIT
—
P/B Ratio
13.88
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-2,112.96 %
Last updated Nov 13, 2026, 3:50 AM

Genincode Peer Group

Genincode Ticker

FRANKFURT · 9PL.FLONDON · GENI.LLONDON STOCK EXCHANGE · GENI.L

Genincode FIGI

GENI:LN · BBG011WG2CQ8GENIGBX:XH · BBG011X1GCR4GENIGBX:XF · BBG011X1GCT2GENIGBX:XE · BBG011X1GCW8GENIGBX:XL · BBG011X1GCY6GENIGBX:XG · BBG011X1GCZ5GENIGBX:XO · BBG011X1GD01GENIGBX:XA · BBG011X1GD47GENIGBX:XT · BBG011X1GD65GENIGBX:XW · BBG011X1GD74GENIGBX:XU · BBG011X1GD83GENIGBX:XV · BBG011X1GDB9

All fundamentals and in-depth analysis of Genincode

Our stock analysis for Genincode stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genincode. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.